Ocular Therapeutix Highlights Key Scientific Engagements
Ocular Therapeutix, Inc. (NASDAQ: OCUL), a leading biopharmaceutical company focused on enhancing patient outcomes through innovative retina therapies, has announced its upcoming participation in a series of influential scientific conferences. These gatherings, happening in the near future, will allow Ocular Therapeutix to showcase its latest research and advancements in ocular treatments.
Participation in Major Conferences
The company will feature prominently at the 8th Annual OIS Retina Innovation Summit scheduled for late July. Ocular Therapeutix plans to deliver a significant presentation focused on advancements in drug delivery methods that can greatly benefit those managing retinal diseases.
Conference Details:
On July 29, the spotlight will be on the company's initiatives under the session "Spotlight on Drug Delivery." Scheduled for 11:00 AM to 12:35 PM PT, the presentation will be led by Sanjay Nayak, MBBS, PhD, the Chief Strategy Officer. This session promises to explore innovative approaches in delivering ocular therapy effectively.
Panel Involvement:
Additionally, the company will be represented on a panel discussion enhancing the dialogue around effective delivery systems in ophthalmic treatments, where Dr. Peter K. Kaiser, MD, the Chief Development Officer, will contribute insights valuable to industry practitioners.
Engagement with the ASRS
Ocular Therapeutix is also set to engage with attendees at the American Society of Retinal Specialists (ASRS) 43rd Annual Scientific Meeting, which is a vital platform for professionals within the retina specialty. The company’s researchers will present groundbreaking findings about the longitudinal quantitative assessment of retinal leakage in diabetic retinopathy during the Diabetic Retinopathy Symposium 2.
Presentation Highlights:
This session, to be held on July 31 from 11:35 AM to 12:15 PM PT, features Katherine Talcott, MD, who will discuss their work related to the HELIOS Trial and its implications for the treatment of diabetic retinopathy. Furthermore, a poster detailing the macular volumetric fluid outcomes from a recent study will also be presented, showcasing Devesh Kumar, MD as the leading presenter.
Spotlight on Women in Ophthalmology
Ocular Therapeutix is not just limited to retinal specialists but is also participating in the Women in Ophthalmology (WIO) 2025 conference on Amelia Island, Florida. They will deliver a poster session that further elucidates findings on macular fluid volume and leakage analysis post-treatment with their proprietary intravitreal hydrogel, presenting a unique approach to diabetes-related retinal complications.
Poster Session Insights:
The poster session will occur on August 9 and 10, covering findings essential for those involved in managing diabetic retinopathy. Diana Do, MD will take center stage presenting these insights during crucial networking sessions.
Innovative Products and Research at Ocular Therapeutix
Ocular Therapeutix is continually working on products that aim to redefine the experience of retina treatment. Their investigational candidate, AXPAXLI™ (OTX-TKI), is making strides in clinical trials targeting wet age-related macular degeneration. This is an important focus for the company as they aim to utilize their proprietary ELUTYX™ technology, which enhances the bioresorbable hydrogel formulation, contributing to innovative retinal therapies.
Current Developments:
In addition to AXPAXLI, the company has a diverse pipeline, including DEXTENZA, which is already FDA-approved for ocular inflammation and pain management. Their investigational product OTX-TIC is designed to treat open-angle glaucoma or ocular hypertension and is currently undergoing Phase 2 clinical trials.
Ocular Therapeutix’s Commitment to Innovation
The presence of Ocular Therapeutix at these scientific forums not only highlights their commitment to advancing treatments but also their dedication to engaging with the medical community about potential new standards of care in ocular therapy. By sharing their research and insights, they underscore the importance of collaboration and innovation in the field.
Stay Connected:
To keep abreast of their latest developments, individuals can follow the company's journey through their official website and social media profiles. This engagement is vital as Ocular Therapeutix continues to position itself at the forefront of retina therapeutic innovation.
Frequently Asked Questions
1. What does Ocular Therapeutix specialize in?
Ocular Therapeutix is a biopharmaceutical company focused on developing innovative therapies for the retina and ocular diseases.
2. What conferences are they participating in?
They will attend the OIS Retina Innovation Summit, ASRS Annual Scientific Meeting, and the Women in Ophthalmology conference.
3. Who will present at these conferences?
Sanjay Nayak, Katherine Talcott, Devesh Kumar, and Diana Do will lead the presentations.
4. What is AXPAXLI™?
AXPAXLI™ is an investigational product candidate being developed for treating wet age-related macular degeneration.
5. How can I stay updated on Ocular Therapeutix news?
Follow their updates through their official website and social media channels.
